On this episode of the Business of Eye Innovation Podcast, Medevise Director of Medical Communications and Marketing, Rebecca Rose, talks with LumiThera Co-Founder, President, and CEO Dr. Clark Tedford about the company’s plans for the upcoming DOC congress, their Valeda Light Delivery System, and the LIGHTSITE III study.  Key takeaways:  LumiThera’s Valeda Light Delivery System uses the exciting technology of photobiomodulation (PBM). PBM is a light-based therapy that can stimulate energy production and blood flow and is used in several other therapeutic areas as well. The goal is to use PBM as a non-invasive treatment to help improve visual function, stop or slow progression of debilitating eye disease, and hopefully prevent vision loss and blindness.  The LIGHTSITE III US pivotal topline data show promising results in intermediate patients with dry AMD. The Valeda Light Delivery System has been commercially approved in Europe for the past three years. LumiThera will be present at the upcoming DOC Congress in Nuremberg, Germany. In addition to showcasing at booth Ü19, they are planning a symposium with Prof. Dr. Albert Augustin to serve as moderator and Dr. Clark Tedford, Prof. Dr. Michael Koss, and Dr. Hakan Kaymak to speak about the history of photobiomodulation, dig into the clinical trial data, and share their experience with the Valeda Light Delivery System. This symposium will take place at 14:00 on Friday, June 24th in the Istanbul Room.    Find out more about our guest Dr. Clark Tedford and LumiThera. Download an invitation to the symposium. Connect with Medevise on LinkedIn.